Hamilton Thorne (HTL) Stock Price, News & Analysis

Company Overview

Hamilton Thorne Ltd. develops, manufactures, and sells precision instruments, consumables, software, and services for the assisted reproductive technologies (ART), research, and cell biology markets. It offers precision laser systems, imaging systems, and other equipment and consumables for the ART and developmental biology research markets. The company also provides test laboratory and endotoxin testing services, as well as sperm assays, including Sperm Motility Index and Sperm Penetration; and fresh and cryopreserved mouse embryos supply, and technician training and proficiency testing services. In addition, it manufactures and distributes products for reproductive medicine, including clinical and laboratory equipment and disposables, as well as complete installations of ART clinics; and bench top incubators, programmable freezers, loggers, alarms, cryo storage, and software systems and sensors for the safe preservation of medical and biological specimens used in ART and cell biology applications. Further, the company offers Cell-Tek Microscope Chamber, a product for controlling temperature, air flow, humidification, and air quality; laminar flow workstations, incubators, and related products; and artificial intelligence enabled CASA software, consumables, and image analysis systems for the ART and laboratory markets, as well as acts as a value-added reseller of a range of capital equipment and consumables. It sells its products and services through a direct sales force in the United States, Germany, France, Australia, Denmark, Spain, and the United Kingdom, as well as through distributors to fertility clinics, hospitals, pharmaceutical companies, biotechnology companies, educational institutions, and other commercial and academic research establishments in approximately 75 countries. The company is headquartered in Beverly, Massachusetts.

Key Stats

• Today's Range: C$1.42 to C$1.45
• 50-Day Range: C$1.45 to C$1.45
• 52-Week Range: C$1.25 to C$1.73
• Volume: 25,700 shs
• Average Volume: 35,118 shs
• Market Capitalization: C$149.69 million
• P/E Ratio: 58.94
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

HTL Stock Analysis - Frequently Asked Questions

How have HTL shares performed this year?

Hamilton Thorne's stock was trading at C$1.45 on January 1st, 2025. Since then, HTL shares have increased by 0.0% and is now trading at C$1.45.

How do I buy shares of Hamilton Thorne?

Shares of HTL stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of Hamilton Thorne own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Hamilton Thorne investors own include Trican Well Service (TCW), Bank of America (BAC), Intel (INTC), AltaGas (ALA), AutoZone (AZO) and Baidu (BIDU).

Industry, Sector and Symbol

• Stock Exchange: CVE
• Sector: Medical
• Industry: Medical Devices
• Sub-Industry: N/A
• Current Symbol: CVE:HTL
• CIK: N/A
• Web: www.hamiltonthorne.com
• Phone: +1-978-9212050
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): C$0.02
• Trailing P/E Ratio: 58.94
• Forward P/E Ratio: 40.49
• P/E Growth: N/A
• Net Income: C$1.79 million
• Net Margins: 4.65%
• Pretax Margin: N/A
• Return on Equity: 4.55%
• Return on Assets: 1.57%

Debt

• Debt-to-Equity Ratio: 16.60
• Current Ratio: 3.20
• Quick Ratio: 2.25

Sales & Book Value

• Annual Sales: C$38.41 million
• Price / Sales: 3.90
• Cash Flow: C$0.10 per share
• Price / Cash Flow: 14.17
• Book Value: C$0.40 per share
• Price / Book: 3.65

Miscellaneous

• Outstanding Shares: 103,234,368
• Free Float: N/A
• Market Cap: C$149.69 million
• Optionable: Not Optionable
• Beta: 0.54